SUBSCRIBE
SUBSCRIBE
Pharm Country

FDA Approves Bristol-Myers Squibb Company, AstraZeneca PLC Kidney Disease Label for Onglyza

February 24, 2011 | 
1 min read

NEW YORK (AP) -- Bristol-Myers Squibb Co. and AstraZeneca PLC said Wednesday they are expanding the label of their diabetes drug Onglyza, adding information about the drug’s effects in patients with kidney failure.

AstraZeneca Pharmaceuticals LP Bristol Myers Squibb Company Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Mother covering her face, experiencing depression symptoms
Drug Development
Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial
May 3, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Business
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
April 29, 2024
 · 
2 min read
 · 
Tyler Patchen